Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

Similar articles for PubMed (Select 17376835)

1.

Dosing and timing effects of anti-CD40L therapy: predictions from a mathematical model of type 1 diabetes.

Gadkar KG, Shoda LK, Kreuwel HT, Ramanujan S, Zheng Y, Whiting CC, Young DL.

Ann N Y Acad Sci. 2007 Apr;1103:63-8. Epub 2007 Mar 21.

PMID:
17376835
2.

The virtual NOD mouse: applying predictive biosimulation to research in type 1 diabetes.

Zheng Y, Kreuwel HT, Young DL, Shoda LK, Ramanujan S, Gadkar KG, Atkinson MA, Whiting CC.

Ann N Y Acad Sci. 2007 Apr;1103:45-62. Epub 2007 Mar 21.

PMID:
17376834
3.
4.

Mechanisms mediating anti-CD3 antibody efficacy: insights from a mathematical model of type 1 diabetes.

Young DL, Ramanujan S, Kreuwel HT, Whiting CC, Gadkar KG, Shoda LK.

Ann N Y Acad Sci. 2006 Oct;1079:369-73.

PMID:
17130581
5.

The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse.

Shoda L, Kreuwel H, Gadkar K, Zheng Y, Whiting C, Atkinson M, Bluestone J, Mathis D, Young D, Ramanujan S.

Clin Exp Immunol. 2010 Aug;161(2):250-67. doi: 10.1111/j.1365-2249.2010.04166.x. Epub 2010 May 18.

6.

Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse.

Komura K, Fujimoto M, Yanaba K, Matsushita T, Matsushita Y, Horikawa M, Ogawa F, Shimizu K, Hasegawa M, Takehara K, Sato S.

Ann Rheum Dis. 2008 Jun;67(6):867-72. Epub 2007 Sep 6.

PMID:
17823201
7.

Human alpha 1-antitrypsin therapy induces fatal anaphylaxis in non-obese diabetic mice.

Lu Y, Parker M, Pileggi A, Zhang B, Choi YK, Molano RD, Wasserfall C, Ricordi C, Inverardi L, Brantly M, Schatz D, Atkinson M, Song S.

Clin Exp Immunol. 2008 Oct;154(1):15-21. doi: 10.1111/j.1365-2249.2008.03721.x. Epub 2008 Aug 28.

8.

Resistance to the induction of mixed chimerism in spontaneously diabetic NOD mice depends on the CD40/CD154 pathway and donor MHC disparity.

Luo B, Wu T, Pan Y, Sozen H, Hao J, Zhang Y, Sutherland DE, Hering BJ, Guo Z.

Ann N Y Acad Sci. 2007 Apr;1103:94-102. Epub 2007 Mar 21.

PMID:
17376827
9.

Mechanisms underlying B-cell tolerance induction by antigen-immunoglobulin G gene transfer.

Wang R, Wang J, Han G, Song L, Chen G, Xu R, Yu M, Qian J, Shen B, Li Y.

J Int Med Res. 2007 Nov-Dec;35(6):781-9.

PMID:
18034991
10.

A comprehensive review of interventions in the NOD mouse and implications for translation.

Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, Kahn R, Kreuwel HT.

Immunity. 2005 Aug;23(2):115-26. Review.

11.

B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.

Xiu Y, Wong CP, Bouaziz JD, Hamaguchi Y, Wang Y, Pop SM, Tisch RM, Tedder TF.

J Immunol. 2008 Mar 1;180(5):2863-75.

12.

Transient anti-CD40L co-stimulation blockade prevents immune responses against human bullous pemphigoid antigen 2: implications for gene therapy.

Lanschuetzer CM, Olasz EB, Lazarova Z, Yancey KB.

J Invest Dermatol. 2009 May;129(5):1203-7. doi: 10.1038/jid.2008.364. Epub 2008 Nov 27.

13.

Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.

Ishikawa H, Ochi H, Chen ML, Frenkel D, Maron R, Weiner HL.

Diabetes. 2007 Aug;56(8):2103-9. Epub 2007 Apr 24.

14.

Interferon-tau inhibits the development of diabetes in NOD mice.

Sobel DO, Ahvazi B, Amjad F, Mitnaul L, Pontzer C.

Autoimmunity. 2008 Nov;41(7):543-53. doi: 10.1080/08916930802194195.

PMID:
18608174
15.

Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice.

Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong FS, Shlomchik MJ, Wen L.

J Clin Invest. 2007 Dec;117(12):3857-67.

16.

Cannabidiol arrests onset of autoimmune diabetes in NOD mice.

Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, Gallily R.

Neuropharmacology. 2008 Jan;54(1):244-9. Epub 2007 Jul 17.

17.

Anti-CD20 treatment prolongs syngeneic islet graft survival and delays the onset of recurrent autoimmune diabetes.

Hu C, Deng S, Wong FS, Wen L.

Ann N Y Acad Sci. 2008 Dec;1150:217-9. doi: 10.1196/annals.1447.032.

PMID:
19120299
18.

Suppression of type 1 diabetes in NOD mice by bifunctional peptide inhibitor: modulation of the immunological synapse formation.

Murray JS, Oney S, Page JE, Kratochvil-Stava A, Hu Y, Makagiansar IT, Brown JC, Kobayashi N, Siahaan TJ.

Chem Biol Drug Des. 2007 Sep;70(3):227-36.

PMID:
17718717
19.

Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth.

Roep BO.

Ann N Y Acad Sci. 2007 Apr;1103:1-10. Epub 2007 Mar 21. Review.

PMID:
17376838
20.

Generation and characterization of a novel anti-rat CD40L antibody with inhibitory activities in vitro and in vivo.

Stax AM, Gelderman KA, Kamerling SW, van der Geest R, Schlagwein N, van Kooten C.

J Immunol Methods. 2008 Jun 1;335(1-2):46-52. doi: 10.1016/j.jim.2008.02.013. Epub 2008 Mar 20.

PMID:
18384807
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk